1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,360 | 1,480 | 20:58 | |
| 1,400 | 1,440 | 21:01 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19:18 | MaxCyte reports Q3 results | 1 | Seeking Alpha | ||
| 14:12 | MaxCyte, Inc: MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance | 57 | GlobeNewswire (Europe) | MaxCyte will now host its earnings conference call on November 12, 2025 Management will present at the Stifel Healthcare Conference on November 11, 2025 and Stephens Investment Conference on November... ► Artikel lesen | |
| 08.10. | MaxCyte, Inc: MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025 | 3 | GlobeNewswire (USA) | ||
| 06.10. | MaxCyte, Inc: MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors | 257 | GlobeNewswire (Europe) | ROCKVILLE, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and... ► Artikel lesen | |
| MAXCYTE Aktie jetzt für 0€ handeln | |||||
| 22.09. | MaxCyte announces 34% workforce reduction to cut costs | 1 | Seeking Alpha | ||
| 22.09. | MAXCYTE, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.09. | MaxCyte, Inc: MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability | 177 | GlobeNewswire (Europe) | ROCKVILLE, Md., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development... ► Artikel lesen | |
| 26.08. | MAXCYTE, INC. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 11.08. | MaxCyte stock rating downgraded to Neutral by BTIG on funding concerns | 11 | Investing.com | ||
| 07.08. | MaxCyte stock downgraded by William Blair to Market Perform on weak guidance | 2 | Investing.com | ||
| 07.08. | MaxCyte revises 2025 core revenue guidance to $29.5M-$32.5M amid customer program consolidation | 1 | Seeking Alpha | ||
| 06.08. | MaxCyte Q3 2025 presentation slides: SPL portfolio expands despite market challenges | 3 | Investing.com | ||
| 06.08. | MAXCYTE, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.08. | MAXCYTE, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.08. | MaxCyte, Inc: MaxCyte Signs Platform License Agreement with Adicet Bio | 275 | GlobeNewswire (Europe) | MaxCyte's Flow Electroporation® technology and ExPERT platform to support development of Adicet's gamma delta T cell therapy gene edited programs ROCKVILLE, Md., Aug. 04, 2025 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| 31.07. | MaxCyte, Inc: MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline | 172 | GlobeNewswire (Europe) | ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development... ► Artikel lesen | |
| 09.07. | MaxCyte, Inc: MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025 | 4 | GlobeNewswire (USA) | ||
| 26.06. | XFRA MYE0: WIEDERAUFNAHME/RESUMPTION | 350 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 26.06. | XFRA MYE0: AUSSETZUNG/SUSPENSION | 199 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILMAXCYTE INC DL-... ► Artikel lesen | |
| 26.06. | AIM - Cancellation - Maxcyte Inc | 1 | RNS |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANGAMO THERAPEUTICS | 0,490 | +0,41 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call | ||
| IMMATICS | 7,820 | -2,92 % | Immatics Appoints Amie Krause as Chief People Officer | Houston, Texas and Tuebingen, Germany, October 27, 2025 - Immatics N.V.as a means of disclosing material non-public information. For regular updates, you can also follow us on LinkedInand Instagram.Forward-Looking... ► Artikel lesen | |
| ALDEYRA | 4,226 | -1,49 % | Aldeyra reshuffles pipeline, culling asset despite Phase II success | ||
| MEDIFAST | 10,660 | +2,01 % | Medifast's Q3 Loss Wider Than Expected, Sales Decline 36% Y/Y | ||
| PHARMING | 1,112 | -2,20 % | Pharming Group N.V.: Pharming Group to participate in Fireside Chat at Jefferies Global Healthcare Conference in London | Leiden, the Netherlands, October 30, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will participate in the Jefferies Global Healthcare... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,393 | +3,49 % | Coherus Oncology, Inc.: Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025 | ||
| ORUKA THERAPEUTICS | 23,200 | -3,33 % | Oruka Therapeutics, Inc.: Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001 | Half-life of approximately 100 days increases likelihood of once-per-year dosing Pharmacokinetic profile supports the ability to achieve exposures that could lead to higher efficacy and extended... ► Artikel lesen | |
| ARMATA PHARMACEUTICALS | 4,140 | +1,47 % | XFRA TG1N: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| INNOVIVA | 15,800 | 0,00 % | Innoviva Specialty Therapeutics, Inc.: FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025 | FDA is expected to notify Innoviva Specialty Therapeutics regarding its decision to conduct an Advisory Committee Meeting in the Day 74 letter If approved, zoliflodacin would be the first new... ► Artikel lesen | |
| BRAINSTORM CELL THERAPEUTICS | 0,673 | -100,00 % | BrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update | Conference call and webcast scheduled for 8:30 a.m. Eastern Time Today, Thursday, August 14, 2025
NEW YORK, Aug. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 8,440 | +3,69 % | SIGA Technologies Inc.: SIGA to Host Business Update Call on November 6, 2025 Following Release of Third-Quarter 2025 Results | ||
| DBV TECHNOLOGIES | 2,495 | -4,22 % | DBV Technologies S.A.: DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference | Châtillon, France, November 4, 2025
DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq... ► Artikel lesen | |
| LIQUIDIA | 22,800 | -6,17 % | Liquidia Technologies, Inc.: Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Recorded $51.7 million in net product sales of YUTREPIA as launch momentum continuesAchieved profitability in the first full quarter of YUTREPIA salesMore than 2,000 unique patient prescriptions and... ► Artikel lesen | |
| SYNDAX PHARMACEUTICALS | 13,100 | -2,24 % | Syndax Pharmaceuticals, Inc.: Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update | - $45.9 million in total revenue, representing 21% growth over 2Q25 - - $32.0 million Revuforj® (revumenib) net revenue; total Revuforj prescriptions in 3Q25 increased 25% over 2Q25, highlighting... ► Artikel lesen | |
| MATINAS BIOPHARMA | 1,250 | -8,76 % | Matinas BioPharma Holdings, Inc. - 8-K, Current Report |
Das Unternehmen MAXCYTE INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,330 Euro und damit -5,67 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAXCYTE INC finden Sie auf Wallstreet Online.